Today: 17 May 2026
Rubico stock jumps in premarket after tanker owner pegs NAV at $94.2 million
3 March 2026
1 min read

Rubico stock jumps in premarket after tanker owner pegs NAV at $94.2 million

New York, March 3, 2026, 06:42 (EST) — Premarket

  • Premarket trading saw shares jump roughly 53%, building on Monday’s steep rally.
  • Rubico put its net asset value estimate at $94.2 million as of Dec. 31, 2025
  • CEO Kalliopi Ornithopoulou put the stock at about a 94% discount to fully diluted NAV.

Rubico Inc surged 53% to $1.55 ahead of Tuesday’s open, following a 20% climb to $1.01 the previous day. Monday’s session saw the stock move from $0.94 to $1.32, with volume hitting roughly 17.7 million shares.

Rubico on March 2 disclosed its net asset value stood at $94.2 million as of December 31, 2025, using broker estimates for charter-free vessel prices, factoring in debt and cash. CEO Kalliopi Ornithopoulou flagged that the shares were trading at a steep 94.4% discount to Rubico’s fully diluted NAV. She also cited existing time-charter contracts, which are locked in through the first quarter of 2031.

Rubico wrapped up Monday’s session with a market cap sitting around $4.1 million—thin enough that a single valuation-themed headline can spark outsized swings. NAV talk hands quick-money traders an easy narrative: asset value stacked against a micro stock price.

Net asset value, often cited in shipping circles, begins with the estimated resale value of the fleet. Cash on hand gets tacked on; debt is taken off.

“Fully diluted” refers to the expanded share count a company would show if all potential instruments—think warrants—were exercised. The key: a higher share count chips away at per-share value.

Time charters, in effect ship leases with fixed day rates over a given term, help steady income. But once those deals expire and new rates kick in, owners can find themselves on the hook for sudden drops or jumps in the market.

Rubico runs a tighter ship than most, literally—just two crude tankers make up its fleet. Any swing in vessel pricing or a single contract dispute is enough to throw off the numbers.

Still, NAV is just an estimate—there’s no guarantee it matches a live bid. If tanker prices slide, broker marks can move fast. The company’s diluted figures? Those count on all warrants and prefunded warrants getting exercised, so the share count isn’t locked in.

Stock Market Today

  • Realty Income (O) Faces Mixed Valuation Signals After Solid Q1 and Raised AFFO Guidance
    May 17, 2026, 12:49 AM EDT. Realty Income (O) reported strong Q1 results and boosted its Adjusted Funds From Operations (AFFO) guidance, alongside its 671st monthly dividend, equity issuance, and buybacks. Despite these positive developments, its share price fell 6.1% over 30 days and 6.9% over 90 days. The stock trades at a high price-to-earnings (P/E) ratio of 50.9x, well above peer averages, suggesting valuation risk. However, a dividend-focused valuation model indicates the stock is 13.8% undervalued with a fair value of $70.93 compared to the current $61.12 share price. Investors should weigh steady dividend growth and operating margins against rising funding costs and regional revenue risks in Realty Income's western markets.

Latest articles

Joby Aviation Slides Monday With Air-Taxi in Focus

Joby Aviation Slides Monday With Air-Taxi in Focus

17 May 2026
Joby Aviation shares closed Friday at $10.36, down 2.6% for the day and 4.7% for the week. CEO JoeBen Bevirt-linked trusts sold over 421,000 shares under a preset 10b5-1 plan, filings showed. The stock traded between $10.04 and $10.58 during a volatile week. Broader markets and eVTOL sector peers also declined.
ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

17 May 2026
ImmunityBio closed at $7.97 Friday, down 2.2% after announcing exclusive U.S. rights to Japan BCG Laboratory’s Tokyo-172 strain for bladder cancer therapy. The Tokyo strain remains investigational in the U.S. and is not FDA-approved. Nasdaq was closed for the weekend; the next trading session is Monday. ImmunityBio’s Q1 product revenue rose to $44.2 million with $380.9 million in cash and securities.
Infleqtion Stock Just Took a Hit After Record Revenue — What Could Move INFQ Next

Infleqtion Stock Just Took a Hit After Record Revenue — What Could Move INFQ Next

17 May 2026
Infleqtion Inc. shares fell 10.95% to $12.44 Friday, capping a rough week for quantum tech stocks. The company reported a first-quarter net loss of $30.3 million on $9.5 million in revenue, with 85% from government contracts. Infleqtion launched a new RF sensing platform and raised its 2026 revenue outlook, but warned of continued operating losses.
Synopsys Shares Dropped for the Week, Looking to May 27 for Direction

Synopsys Shares Dropped for the Week, Looking to May 27 for Direction

17 May 2026
Synopsys shares fell 1.49% Friday to $502.42, ending the week down 2.72% amid a broad tech selloff and news that Coatue Management cut its stake by 54%. The Nasdaq Composite dropped 1.54% Friday, while the Philadelphia semiconductor index slid 4%. Synopsys will report fiscal Q2 results after the market closes on May 27. Wells Fargo and Citigroup raised their price targets for the stock earlier in the week.
BATL stock steadies in premarket after doubling as Hormuz fears lift oil — what’s next for Battalion Oil
Previous Story

BATL stock steadies in premarket after doubling as Hormuz fears lift oil — what’s next for Battalion Oil

MARA stock jumps premarket as annual filing opens door to selling bitcoin stash
Next Story

MARA stock jumps premarket as annual filing opens door to selling bitcoin stash

Go toTop